Chemokine receptor CXCR3 promotes growth of glioma

Carcinogenesis

Volumn 32, Issue 2, 2011, Pages 129-137

  Liu, Che ^a   Luo, Defang ^a   Reynolds, Brent A ^a   Meher, Geeta ^b   Katritzky, Alan R ^b   Lu, Bao ^a,c   Gerard, Craig J ^c   Bhadha, Cyrus P ^a   Harrison, Jeffrey K ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Children's Hospital and Harvard Medical School ^*  (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; NBI 74330; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INFILTRATION; CANCER SURVIVAL; CONTROLLED STUDY; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 79251541774     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq224     Document Type: Article

References (48)

1. Kawakami,Y. et al. (2008) Dendritic cell based personalized immunotherapy based on cancer antigen research. Front. Biosci., 13, 1952-1958.
2. Vandercappellen,J. et al. (2008) The role of CXC chemokines and their receptors in cancer. Cancer Lett., 267, 226-244.
3. Curbishley,S.M. et al. (2005) CXCR 3 activation promotes lymphocyte transendothelial migration across human hepatic endothelium under fluid flow. Am. J. Pathol., 167, 887-899.
4. Wendel,M. et al. (2008) Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res., 68, 8437-8445.
5. Rappert,A. et al. (2004) CXCR3-dependent microglial recruitment is essential for dendrite loss after brain lesion. J. Neurosci., 24, 8500-8509.
6. Wenzel,J. et al. (2005) Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. Am. J. Clin. Pathol., 124, 37-48.
7. Chu,Y. et al. (2007) In situ expression of IFN-gamma-inducible T cell alpha chemoattractant in breast cancer mounts an enhanced specific anti-tumor immunity, which leads to tumor regression. Cancer Immunol. Immunother., 56, 1539-1549.
8. Hensbergen,P.J. et al. (2005) The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. J. Immunother., 28, 343-351.
9. Walser,T.C. et al. (2006) Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res., 66, 7701-7707.
10. Datta,D. et al. (2006) Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res., 66, 9509-9518.
11. Goldberg-Bittman,L. et al. (2004) The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunol. Lett., 92, 171-178.
12. Kawada,K. et al. (2004) Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res., 64, 4010-4017.
13. Kawada,K. et al. (2007) Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene, 26, 4679-4688.
14. Suyama,T. et al. (2005) Up-regulation of the interferon gamma (IFNgamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma. Cancer, 103, 258-267.
15. Furuya,M. et al. (2007) Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. Hum. Pathol., 38, 1676-1687.
16. Jones,D. et al. (2000) The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood, 95, 627-632.
17. Engl,T. et al. (2006) Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci., 78, 1784-1793.
18. Ma,X. et al. (2009) CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol. Cancer Ther., 8, 490-498.
19. Monteagudo,C. et al. (2007) CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors. J. Clin. Pathol., 60, 596-599.
20. Giuliani,N. et al. (2006) CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica, 91, 1489-1497.
21. Pradelli,E. et al. (2009) Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs. Int. J. Cancer, 125, 2586-2594.
22. Zipin-Roitman,A. et al. (2007) CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res., 67, 3396-3405.
23. Pellegatta,S. et al. (2006) Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res., 66, 10247-10252.
24. Maru,S.V. et al. (2008) Chemokine production and chemokine receptor expression by human glioma cells: role of CXCL10 in tumour cell proliferation. J. Neuroimmunol., 199, 35-45.
25. Ausman,J.I. et al. (1970) Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res., 30, 2394-2400.
26. Szatmari,T. et al. (2006) Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci., 97, 546-553.
27. Liu,C. et al. (2008) CX3CL1 and CX3CR1 in the GL261 murine model of glioma: CX3CR1 deficiency does not impact tumor growth or infiltration of microglia and lymphocytes. J. Neuroimmunol., 198, 98-105.
28. Heise,C.E. et al. (2005) Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist. J. Pharmacol. Exp. Ther., 313, 1263-1271.
29. Jopling,L.A. et al. (2007) Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay. Br. J. Pharmacol., 152, 1260-1271.
30. Verzijl,D. et al. (2008) Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptors. J. Pharmacol. Exp. Ther., 325, 544-555.
31. van Wanrooij,E.J. et al. (2008) CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol., 28, 251-257.
32. Hancock,W.W. et al. (2000) Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J. Exp. Med., 192, 1515-1520.
33. Harrison,J.K. et al. (2003) In situ hybridization analysis of chemokines and chemokine receptors in the central nervous system. Methods, 29, 312-318.
34. De Witt Hamer,P.C. et al. (2008) The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene, 27, 2091-2096.
35. Lee,J. et al. (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell, 9, 391-403.
36. Lasagni,L. et al. (2003) An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and ITAC, and acts as functional receptor for platelet factor 4. J. Exp. Med., 197, 537-549.
37. Ehlert,J.E. et al. (2004) Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. J. Immunol., 173, 6234-6240.
38. Carr,D.J. et al. (2008) An increase in herpes simplex virus type 1 in the anterior segment of the eye is linked to a deficiency in NK cell infiltration in mice deficient in CXCR3. J. Interferon Cytokine Res., 28, 245-251.
39. Jiang,D. et al. (2004) Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J. Clin. Invest., 114, 291-299.
40. Muller,M. et al. (2007) CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system. J. Immunol., 179, 2774-2786.
41. Grauer,O.M. et al. (2007) CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int. J. Cancer, 121, 95-105.
42. Kim,J.V. et al. (2010) Two-photon laser scanning microscopy imaging of intact spinal cord and cerebral cortex reveals requirement for CXCR6 and neuroinflammation in immune cell infiltration of cortical injury sites. J. Immunol. Methods, 352, 89-100.
43. Cross,A.K. et al. (1999) Chemokines induce migration and changes in actin polymerization in adult rat brain microglia and a human fetal microglial cell line in vitro. J. Neurosci. Res., 55, 17-23.
44. Kohler,R.E. et al. (2008) Antagonism of the chemokine receptors CXCR3 and CXCR4 reduces the pathology of experimental autoimmune encephalomyelitis. Brain Pathol., 18, 504-516.
45. Balashov,K.E. et al. (1999) CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc. Natl Acad. Sci. USA, 96, 6873-6878.
46. Hiroi,M. et al. (2003) Constitutive nuclear factor kappaB activity is required to elicit interferon-gamma-induced expression of chemokine CXC ligand 9 (CXCL9) and CXCL10 in human tumour cell lines. Biochem. J., 376, 393-402.
47. Petrai,I. et al. (2008) Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B. Int. J. Biochem. Cell Biol., 40, 1764-1774.
48. Romagnani,P. et al. (2001) Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J. Clin. Invest., 107, 53-63.